TFPI2

Across TCGA pan-cancer cohorts, TFPI2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TFPI2 data layer compared with 28 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TFPI2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TFPI2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

CCRCC, PDAC, and LSCC are the cancer types where TFPI2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	II,III,IV	0.325	0.824	.014	17	view →
PDAC	OS	Quartile	All	0.493	0.845	.006	15	view →
LSCC	DFS	Median	All	0.898	0.999	.009	8	view →
UCEC	DFS	Tertile	All	0.972	0.881	.048	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TFPI2–CCRCC (DFS)

Open the CCRCC breakdown →